pentobarbital will decrease the level or result of fosamprenavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will lower the extent or effect of disopyramide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Not known.
pentobarbital will lower the extent or outcome of theophylline by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
Exercise caution each time a barbiturate is administered to your nursing female; little quantities of barbiturates are excreted during the milk
Occasionally, checking at a better standard of take care of tapering CNS depressants can be ideal. In Some others, little by little tapering a client off of a prescribed benzodiazepine or other CNS depressant or decreasing to the bottom helpful dose may very well be ideal.Really serious - Use Different (1)buprenorphine, long-performing injection and pentobarbital both of those raise sedation. Keep away from or Use Alternate Drug. Limit use to people for whom different remedy alternatives are inadequate
pentobarbital will reduce the extent or result of apremilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Coadministration with potent CYP inducers ends in a significant lessen of systemic exposure of apremilast, which can result in lack of efficacy
With therapeutic doses of TCAs, barbiturates maximize metabolism and decrease blood concentrations of TCAs.
Phenytoin and barbiturate blood ranges really should be monitored more usually if specified concurrently; impact of barbiturates on phenytoin metabolism documented to generally be variable; sodium valproate and valproic acid appear to lower barbiturate metabolism; observe barbiturate blood amounts and make suitable dosage adjustments as necessary
pentobarbital will decrease the extent or influence of venetoclax by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
buprenorphine transdermal and pentobarbital each maximize sedation. Steer clear of or Use Alternate Drug. Restrict use to patients for whom choice therapy selections are inadequate
pentobarbital decreases amounts of elvitegravir/cobicistat/emtricitabine/tenofovir DF by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Could produce loss of virologic reaction and possible more info resistance.
With therapeutic doses of TCAs, barbiturates enhance metabolism and decrease blood concentrations of TCAs.
pentobarbital will lower the extent or outcome of nilotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will decrease the extent or outcome of nitrendipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unknown.